Evidence map›Paper›PMID 27377653›Full record

ArticleJournal of neuro-oncology2016

Does the choice of antiepileptic drug affect survival in glioblastoma patients?

Kristin M Knudsen-Baas, Anders Engeland, Nils Erik Gilhus, Anette M Storstein, Jone F Owe

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Management of epilepsy in brain tumors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Guideline
  3. Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Brain Tumor Networks in Diffuse Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kristin M Knudsen-BaasDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway. kristinmkb@hotmail.com.
Anders EngelandDepartment of Pharmacoepidemiology, Domain of Mental and Physical Health, Norwegian Institute of Public Health, 5020, Bergen, Norway.
Nils Erik GilhusDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Anette M StorsteinDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Jone F OweDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Haukeland University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with glioblastoma (GBM) often suffer from symptomatic epilepsy. Older antiepileptic drugs (AEDs) which affect the enzyme system cytochrome P450 have been in extensive use, but there is an increasing focus on interactions with other drugs. This study investigated whether newer AEDs with little or no enzyme effect are increasingly preferred. Previous research has indicated that valproate improves survival in GBM. We investigated the impact of AEDs on overall survival in GBM patients. All GBM patients diagnosed in Norway 2004-2010 were included through a linkage of national registries, and follow-up data on the malignancy and drug usage were analyzed. In a multivariate cox proportional-hazards regression, AEDs were adjusted for each other and for relevant factors. Immortal time bias was eliminated with time-dependent variables. The study population was 1263 patients with histologically confirmed GBM. Carbamazepine was the most frequently prescribed AED to patients diagnosed with GBM during 2004-2006, while levetiracetam was increasingly prescribed to patients diagnosed later. Taking AEDs on a reimbursement code of epilepsy was not beneficial for survival. None of the six AEDs valproate, levetiracetam, carbamazepine, oxcarbazepine, lamotrigine or phenytoin significantly altered overall survival. There has been a shift in the prescriptions of AEDs to GBM patients from older to newer AEDs over time. We found no significant survival benefit in GBM patients neither from treatment with AEDs for epilepsy in general, nor from the usage of six separate AEDs.

Indexed as

Brain NeoplasmsGlioblastomaAdolescentAdultAgedAge DistributionAnticonvulsantsChildChild, PreschoolEpilepsyFemaleHumansInfantKaplan-Meier EstimateMaleMiddle AgedAnticonvulsantsAntiepileptic drugsEpilepsyGlioblastomaNational registriesOverall survival

Identifiers

PMID27377653
OpenAlexW2465214707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.